Tri Locum Partners
Latest statistics and disclosures from Tri Locum Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TEVA, ARGX, ASND, AMGN, NTRA, and represent 39.25% of Tri Locum Partners's stock portfolio.
- Added to shares of these 10 stocks: AMGN (+$26M), INSM (+$21M), ARGX (+$20M), PFE (+$17M), AXSM (+$16M), UTHR (+$16M), ASND (+$16M), INSP (+$15M), ALNY (+$11M), STVN (+$10M).
- Started 10 new stock positions in PFE, INSM, NVO, PCVX, KRRO, ALNY, UTHR, AMGN, OCUL, STVN.
- Reduced shares in these 10 stocks: Silk Road Medical Inc Common (-$20M), , , BAX (-$14M), TNDM (-$12M), , LYRA (-$6.1M), ATXS (-$5.2M), Alpine Immune Sciences, ARCT.
- Sold out of its positions in Alpine Immune Sciences, ARQT, ARCT, ATXS, BAX, EXAS, IsoRay, LYRA, MRK, Silk Road Medical Inc Common. TNDM, VRTX.
- Tri Locum Partners was a net buyer of stock by $107M.
- Tri Locum Partners has $396M in assets under management (AUM), dropping by 37.15%.
- Central Index Key (CIK): 0001826434
Tip: Access up to 7 years of quarterly data
Positions held by Tri Locum Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 25 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 10.5 | $41M | +15% | 2.6M | 16.25 |
|
| Argenx Se Sponsored Adr (ARGX) | 8.1 | $32M | +166% | 75k | 430.04 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 7.9 | $31M | +102% | 228k | 136.38 |
|
| Amgen (AMGN) | 6.5 | $26M | NEW | 82k | 312.45 |
|
| Natera (NTRA) | 6.3 | $25M | +21% | 231k | 108.29 |
|
| Axsome Therapeutics (AXSM) | 6.2 | $25M | +198% | 307k | 80.50 |
|
| Insmed Com Par $.01 (INSM) | 5.4 | $21M | NEW | 317k | 67.00 |
|
| Merus N V (MRUS) | 5.0 | $20M | +17% | 336k | 59.17 |
|
| Regeneron Pharmaceuticals (REGN) | 4.7 | $18M | +104% | 18k | 1051.03 |
|
| Madrigal Pharmaceuticals (MDGL) | 4.6 | $18M | +22% | 65k | 280.16 |
|
| Inspire Med Sys (INSP) | 4.5 | $18M | +465% | 133k | 133.83 |
|
| Avadel Pharmaceuticals Sponsored Adr | 4.2 | $17M | 1.2M | 14.06 |
|
|
| Pfizer (PFE) | 4.2 | $17M | NEW | 597k | 27.98 |
|
| United Therapeutics Corporation (UTHR) | 4.0 | $16M | NEW | 50k | 318.55 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 4.0 | $16M | +25% | 357k | 44.29 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.8 | $11M | NEW | 45k | 243.00 |
|
| Stevanato Group S P A Ord Shs (STVN) | 2.6 | $10M | NEW | 565k | 18.34 |
|
| Novo-nordisk A S Adr (NVO) | 2.3 | $9.1M | NEW | 64k | 142.74 |
|
| Vaxcyte (PCVX) | 2.2 | $8.6M | NEW | 113k | 75.51 |
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $4.0M | -50% | 102k | 38.99 |
|
| Ocular Therapeutix (OCUL) | 0.9 | $3.5M | NEW | 515k | 6.84 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.8 | $3.1M | -29% | 75k | 41.36 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.7 | $2.8M | 382k | 7.21 |
|
|
| Korro Bio (KRRO) | 0.6 | $2.4M | NEW | 71k | 33.87 |
|
| Femasys (FEMY) | 0.0 | $35k | 31k | 1.14 |
|
Past Filings by Tri Locum Partners
SEC 13F filings are viewable for Tri Locum Partners going back to 2020
- Tri Locum Partners 2024 Q2 filed Aug. 14, 2024
- Tri Locum Partners 2024 Q1 filed May 15, 2024
- Tri Locum Partners 2023 Q4 filed Feb. 14, 2024
- Tri Locum Partners 2023 Q3 filed Nov. 14, 2023
- Tri Locum Partners 2023 Q2 filed Aug. 14, 2023
- Tri Locum Partners 2023 Q1 filed May 15, 2023
- Tri Locum Partners 2022 Q4 filed Feb. 14, 2023
- Tri Locum Partners 2022 Q3 filed Nov. 14, 2022
- Tri Locum Partners 2022 Q2 filed Aug. 15, 2022
- Tri Locum Partners 2022 Q1 filed May 16, 2022
- Tri Locum Partners 2021 Q4 filed Feb. 14, 2022
- Tri Locum Partners 2021 Q3 filed Nov. 15, 2021
- Tri Locum Partners 2021 Q2 filed Aug. 16, 2021
- Tri Locum Partners 2021 Q1 filed May 17, 2021
- Tri Locum Partners 2020 Q4 filed Feb. 16, 2021